Observational studyCancer science2024

Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).

Megumi Furuta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.